N4 Pharma updates on Nuvec AAV Viral Vector research

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing research work into the use of Nuvec® to enhance the performance of viral vectors.

Through its research programme with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec® can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 (“AAV8”). This follows on from earlier work where the Company showed that Nuvec® increased transduction efficacy of a standard Adenovirus vector.

Specifically, Nuvec® was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma plc Nuvec Oral Delivery Update

    N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery research work. The Company through its research

    N4 Pharma

    N4 Pharma plc Nuvec® R&D and Strategy Update

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The Company’s double loaded siRNA work is

    N4 Pharma

    N4 Pharma launch Interactive Investor Hub

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders,

    N4 Pharma

    N4 Pharma updated investor presentation

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis

    N4 Pharma

    N4 Pharma acquires of a controlling interest in Nanogenics

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited,

    N4 Pharma

    N4 Pharma granting of patent application in the United States

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The University of Queensland has informed the Company that

    N4 Pharma

    N4 Pharma updates on in vitro results for Nuvec®

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further

    N4 Pharma

    N4 Pharma Nuvec well suited for working with siRNA

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The Company has completed the single loading

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary